MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2016 International Congress

    Technology use and impulse control disorders (ICDs) in patients with Parkinson’s disease (PD)

    E.A. Byrd, C.M. Tanner, C.A. Racine, N.B. Galifianakis (San Francisco, CA, USA)

    Objective: To ascertain the prevalence of problematic technology use (Technology-related ICDs, Tech-ICDs) in patients with PD. Background: ICDs are a known complication of PD drugs…
  • 2016 International Congress

    Drug safety in the pharmacotherapy of Parkinson’s disease

    S. Müller-Rebstein, C. Trenkwalder, J. Ebentheuer, C. Culmsee, G. Höglinger (Kassel, Germany)

    Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…
  • 2016 International Congress

    Dropped head syndrome in parkinsonism: Two treatable etiologies not to miss

    P. Termsarasab, S.J. Frucht (New York, NY, USA)

    Objective: To report the etiology of treatable head drop in Parkinson's disease (PD): one patient from rotigotine patch and the other two from neck extensor…
  • 2016 International Congress

    Peri-operative dopaminergic replacement protocol with rotigotine in Parkinson’s disease patients

    L. Abraira del Fresno, L. Ispierto, A.M. Crespo, T. Canento, D. Vilas, M. Gonzalez, F. Sala, L. Morató, J. Sánchez-Ojanguren, R. Álvarez (Barcelona, Spain)

    Objective: To evaluate the accomplishment of a peri-operative dopaminergic replacement protocol established in our centre from 2011 to 2014, and analyse the main factors associated…
  • 2016 International Congress

    The relationship between impulse control disorders and dyskinesia in Parkinson´s disease: The ALTHEA study

    R.J. Vorovenci, L. Weis, R. Biundo, A. Antonini (Venice, Italy)

    Objective: To report (1) the relationship between the occurrence of impulse control disorders (ICDs) and dyskinesias, and (2) the correlations between specific ICDs and the…
  • 2016 International Congress

    The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson’s disease: Experience from a case report

    R. González-Maldonado, R. González-Redondo, C.G. DiCaudo (Granada, Spain)

    Objective: To describe the clinical effects of combined natural dopaminergic drugs with conventional levodopa therapy in a PD patient with motor and non-motor complications. Background:…
  • 2016 International Congress

    The dopamine agonist withdrawal syndrome rating scale (DAWS-RS): Initial development of a new non-motor scale

    L.S. Croll, K.M. Montgomery, C.V. Kulick, M.J. Nirenberg (New York, NY, USA)

    Objective: To describe the development of the dopamine agonist withdrawal syndrome (DAWS) rating scale (DAWS-RS), a new questionnaire designed to evaluate the symptoms, severity, and…
  • 2016 International Congress

    Improving drug discovery using brain oscillations as biomarkers of Parkinson’s disease

    B. Pouyatos, S.J. Perry, D.E. Grigoriadis, R. Maury, C. Bouyssières, C. Roucard, V. Duveau, Y. Roche (La Tronche, France)

    Objective: The aim of this study was to assess the use of cortical oscillations as translational biomarkers for drug development for the motor symptoms of…
  • 2016 International Congress

    Robust sensorimotor deficits in a knock-in mouse model of primary torsion dystonia

    F. Richter, J. Gerstenberger, A. Bauer, C. Helmschrodt, A. Richter (Leipzig, Germany)

    Objective: The aim of present study was to (1) generate more powerful tests to detect robust behavioral alterations in the DYT1 knock-in mouse model of…
  • 2016 International Congress

    Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial

    S. Muzerengi, R.L. Woolley, C. Rick, N. Ives, F. Dowling, R. Gray, C.E. Clarke, PD MED Collaborative Group (Birmingham, United Kingdom)

    Objective: To compare hospitalisation rates of Parkinson's disease (PD) patients randomised between three different classes of oral medications used for early PD treatment. Background: PD…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley